Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality.

Our proprietary technologies are in developing sensitive qPCR assays for tumor DNA markers using cfDNA in urine and blood, and robust methods for cfDNA isolation.

Our developments set out to change the way medicine is practiced by detecting primary and recurrent cancers and providing cancer genetics for personalized medicine in a noninvasive urine test. We collaborate with the leaders of biomarker research and clinical specialists to develop highly desired diagnostic/screening tools.